Search
for
Sort by
Research 301–330 of 1000+
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Botanicals With Dermatologic Properties Derived From First Nations Healing: Part 1—Trees
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Treatment Advances for Acne Vulgaris: The Scientific Role of Cannabinoids
- Bio-Nanovesicle-Based Approaches for Hair and Skin Regeneration: An Updated Concise Review
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds
- Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting
- SnapshotDx Quiz: September 2018
- 282 WITHDRAWN
- The role of dutasteride in the treatment of benign prostatic obstruction and related conditions
- The Enticing Path of miR Therapeutics: Difficult but Not without Prospects
- Hair Physiology (Hair Growth, Alopecia, Scalp Treatment, etc.)
- CRISPR/Cas9: A Promising Approach for Alopecia
- Non-hemorrhage-related adverse effects of rivaroxaban
- 5. HIV, Fungal and Infectious Diseases
- Faculty Opinions recommendation of Promising therapies for treating and/or preventing androgenic alopecia.
- Clinical Trials and Hair Loss
- Using Angulation of Implanters at 45 Degrees to the Scalp with the Bevel Facing toward the Skin to Enhance Follicular Entry at Minimal Pressure: A Randomized Clinical Trial in Hair Transplantation
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Oral zinc sulphate in treatment of patients with thallium poisoning: A clinical therapeutic trial
- Autologous Concentrated Growth Factors Combined with Topical Minoxidil for the Treatment of Male Androgenetic Alopecia: A Randomized Controlled Clinical Trial
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Safety and efficacy of tavaborole (AN2690), a novel boron-based molecule, in 3 phase II trials for the topical treatment of toenail onychomycosis
- Clinical Evaluation of Standardized Bhringaraj (Eclipta alba) Extract Tablets in Hair Fall: A 24 Week Prospective Trial
- A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men
- Green formulation of spironolactone loaded chitosan coated nano lipid carrier for treatment of acne vulgaris: a randomized double-blind clinical trial
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies